| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8276.9 | 7474.7 | 6268.3 |
| Other income | 130.3 | 140.7 | 79.0 |
| Total income | 8407.2 | 7615.4 | 6347.3 |
| Profit before exceptional items & tax | 2017.4 | 2059.3 | 1415.5 |
| Exceptional items | 0.0 | 131.3 | 0.0 |
| Profit before tax | 2017.4 | 1928.0 | 1415.5 |
| Net profit | 1415.0 | 1460.4 | 1219.1 |
| Operating margin | 24.0% | 25.3% | 22.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +16.10% |
|---|---|
| Net profit, quarter on quarter | -3.10% |
| Revenue, year on year | +32.00% |
| Operating profit, year on year | +41.20% |
| Operating profit, quarter on quarter | -1.60% |
NSE results filing, NSE: LUPIN. Figures extracted from the filing.
Lupin Ltd: key numbers
- Share price
- ₹2,092.00
- Market cap
- ₹95,665 Cr
- Revenue (annual)
- ₹27,958 Cr
- Net profit (annual)
- ₹5,333 Cr
- P/E (TTM)
- 17.3×Sector 50.4×
- Promoter holding
- 46.85%-0.01% QoQ
- FII holding
- 22.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lupin Ltd
All →Lupin Employee Stock Options
Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.
Lupin Product Launch
Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.
Lupin Earnings Call Transcript: Key Takeaways
Lupin reported record Q1 FY27 revenues of ₹8,277 crore with strong EBITDA margins of 30%. Growth was broad-based across US and India, though management expects near-term US moderation due to increased competition in key products.
Lupin Investor Presentation: Key Takeaways
Lupin delivered strong Q1 FY27 results with 33% YoY revenue growth and healthy 30% EBITDA margins, driven by outperformance in US and India markets.
Lupin Q1 FY27 Results: Net Profit ₹1,417 Cr, Up 16.0% YoY
Lupin Ltd reported revenue from operations of ₹8,277 Cr (+32.0% YoY) and net profit of ₹1,417 Cr (+16.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1,417 Cr · +16.0% YoY
Lupin Earnings Call: Key Takeaways
Lupin reported record FY26 revenues of ₹27,958 cr (up 23%) and EBITDA of ₹8,160 cr (up 55%). Management focuses on complex products and India prescription growth.